INTL GENIUS (00033): Executive Director Pan Qingduo appointed as Authorized Representative

22:45 15/06/2026

INTL GENIUS (00033) announced that Ms. Leung Ka Wing (Ms. Leung) has resigned from the company as Company Secretary and Authorized Representative (Authorized Representative) in accordance with Rule 3.05 of the Securities Listing Rules of The Stock Exchange of Hong Kong Limited (HKEX) to devote more time to personal matters, with effect from June 15, 2026.

INTL GENIUS (00033) announced that Ms. Leung Ka-ying (Ms. Leung) has resigned as the Company Secretary and Authorized Representative (Authorized Representative) of the Company, in accordance with Rule 3.05 of the Securities Listing Rules of The Stock Exchange of Hong Kong Limited (the Exchange), as she wishes to dedicate more time to personal matters, effective from June 15, 2026. Following Ms. Leung's resignation, the Board is pleased to announce that Mr. Poon Hing-to has been appointed as the Authorized Representative of the Company, effective from June 15, 2026.

New stock news | Din Tai Pharmaceuticals once again submits an application to the Hong Kong Stock Exchange, becoming the largest CRO in the field of non-clinical research for Chinese cardiovascular and metabolic diseases.

EVEREST MED (01952) has been granted exclusive rights by Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries.

New Stock News | Lico Pharmaceuticals files second application to Hong Kong Stock Exchange for the development of small molecule inhibitors for the treatment of autoimmune and inflammatory diseases.

EVEREST MED (01952) has been granted exclusive rights by Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries.

New Stock News | Lico Pharmaceuticals files second application to Hong Kong Stock Exchange for the development of small molecule inhibitors for the treatment of autoimmune and inflammatory diseases.